


MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. ProMedica Charles & Virginia Hickman Hospital Department of Radiology</p> <p>2. 5640 N Adrian Hwy. Adrian, MI 49221</p>		<p>In accordance with application dated December 13, 2023,</p>	<p>4. Expiration Date: February 28, 2025</p>
		<p>3. License No.: 21-03194-01 is amended in its entirety to read as follows:</p>	<p>5. Docket No.: 030-02027 Reference No.: 030-18540</p>
<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As Needed</p> <p>B. As Needed</p>	<p>9. Authorized use</p> <p>A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.</p> <p>B. For use in imaging and localization studies permitted by 10 CFR 35.200.</p>



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 21-03194-01

Docket or Reference No.:

030-02027

030-18540

Amendment No. 57

CONDITIONS

10. Licensed material shall be used or stored at the licensee's facilities located at 5640 N Adrian Hwy., Adrian, Michigan, 49221.
11. The Radiation Safety Officer (RSO) for this license is Kerry Krugh, Ph.D., DABR.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:
- | <u>Authorized User (M.D.,D.O.,etc.)</u> | <u>Material and Use</u> |
|---|-----------------------------|
| Matthew G. Aagesen, MD | 10 CFR 35.100,10 CFR 35.200 |
| Debra Achinger, MD | 10 CFR 35.100,10 CFR 35.200 |
| Zakaria Ismail Assi, MD | 10 CFR 35.100,10 CFR 35.200 |
| Garett Begeman, MD | 10 CFR 35.100,10 CFR 35.200 |
| Jacob Bieszczad, MD | 10 CFR 35.100,10 CFR 35.200 |
| Felix Q. Boucher, MD | 10 CFR 35.100,10 CFR 35.200 |
| David R. Cervantes, MD | 10 CFR 35.100,10 CFR 35.200 |
| Donald L. Cox, MD | 10 CFR 35.100,10 CFR 35.200 |
| Amy Culler, MD | 10 CFR 35.100,10 CFR 35.200 |
| Laura DeBenedetti, MD | 10 CFR 35.200 |
| Robert S. DiSalle, MD | 10 CFR 35.100,10 CFR 35.200 |
| Farhad Ebrahim, MD | 10 CFR 35.100,10 CFR 35.200 |
| Nathan Egbert, MD | 10 CFR 35.100,10 CFR 35.200 |

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 21-03194-01

Docket or Reference No.:

030-02027

030-18540

Amendment No. 57

Authorized User (M.D.,D.O.,etc.)Material and Use

Mohamed Elamin, MD	10 CFR 35.200
Stephen Eldridge, MD	10 CFR 35.100,10 CFR 35.200
Haitham M. Elsamaloty, MD	10 CFR 35.100,10 CFR 35.200
Murray Howe, MD, PhD	10 CFR 35.100,10 CFR 35.200
Steven Kumar Jindal, MD	10 CFR 35.100,10 CFR 35.200
Vincent J. Keiser, MD	10 CFR 35.100,10 CFR 35.200
Terrence Lewis, MD	10 CFR 35.100,10 CFR 35.200
Mohammed Maaieh, MD	10 CFR 35.200
Hazem Malas, DO	10 CFR 35.200
Tamara Martin, MD	10 CFR 35.100,10 CFR 35.200
Tarek S. Moustafa, MD	10 CFR 35.100,10 CFR 35.200
Jonathan A. Nadaud, MD	10 CFR 35.100,10 CFR 35.200
Thomas Pappas, MD	10 CFR 35.200
Parag U. Parikh, MD	10 CFR 35.100,10 CFR 35.200
Yogesh P. Patel, MD	10 CFR 35.100,10 CFR 35.200
Timothy J. Quinn, MD	10 CFR 35.100,10 CFR 35.200
Zachary Rost, MD	10 CFR 35.100,10 CFR 35.200
Jamal K Saleh, MD	10 CFR 35.100,10 CFR 35.200
Steven K. Shekut, MD	10 CFR 35.100,10 CFR 35.200
Robin B. Shermis, MD	10 CFR 35.100,10 CFR 35.200
Bruce R. Siders, DO	10 CFR 35.100,10 CFR 35.200
Stephen F. Stoll, MD	10 CFR 35.100,10 CFR 35.200
Edward Sutherland, MD	10 CFR 35.100,10 CFR 35.200
Michael A. Walsh, MD	10 CFR 35.100,10 CFR 35.200

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 21-03194-01

Docket or Reference No.:

030-02027

030-18540

Amendment No. 57

Authorized User (M.D.,D.O.,etc.)

Thomas T. Win, MD

Jonathan J. Yobbagy, MD

Material and Use

10 CFR 35.100,10 CFR 35.200

10 CFR 35.100,10 CFR 35.200



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 21-03194-01

Docket or Reference No.:


030-02027

030-18540

Amendment No. 57

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those statements, representations, and procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence impose on the licensee requirements that are more restrictive than or in addition to the regulations.

- A. Application dated August 1, 2014 (ML14234A228)
- B. Letter dated January 14, 2015 (ML15037A561)
- C. Letter dated March 7, 2017 (ML17066A439)
- D. Letter dated February 20, 2020 (ML20052C800)
- E. Letter dated April 20, 2020 (ML20121A134)
- F. Application dated October 15, 2020 (ML20290A482)
- G. Letter dated November 5, 2020 (ML20323A068)
- H. Letter dated December 14, 2020 (ML20351A260)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: January 11, 2024

By: _____

Laura B. Cender
Region 3